期刊文献+
共找到480篇文章
< 1 2 24 >
每页显示 20 50 100
Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China 被引量:7
1
作者 Ke-Hung Tsui Shao-Ming Chen +4 位作者 Ta-Ming Wang Horng-Heng Juang Chien-Lun Chen Guang-Huan Sun Phei-Lang Chang 《Asian Journal of Andrology》 SCIE CAS CSCD 2007年第5期711-715,共5页
Aim: To compare the results of bladder tumor associated antigen (BTA TRAK), nuclear matrix protein 22 (NMP 22) and voided urine cytology (VUC) in detecting bladder cancer. Methods: A total of 135 elderly male ... Aim: To compare the results of bladder tumor associated antigen (BTA TRAK), nuclear matrix protein 22 (NMP 22) and voided urine cytology (VUC) in detecting bladder cancer. Methods: A total of 135 elderly male and 50 healthy volunteers enrolled in this study were classified into three groups: (i) 93 patients with bladder cancer; (ii) 42 patients with urinary benign conditions; and (iii) 50 healthy volunteers. BTA TRAK and NMP 22 kits were used to detect bladder cancer. Voided urine cytology was used to compare the sensitivity and specificity of the screening tests. Results: The sensitivity and specificity of cytology, BTA TRAK and NMP 22 were 24% and 97%, 51% and 73%, 78% and 73%, respectively. The level of NMP 22 increased with tumor grading. The BTA TRAK kit has the lowest sensitivity among the screening tests. The NMP 22 with the best sensitivity can be an adjunct to cytology for evaluating bladder cancer. Conclusion: The NMP 22 test has a better correlation with the grading of the bladder cancer than BTA TRAK. As cytology units are typically not available in hospitals or in outpatient clinics, NMP 22 might be a promising tool for screening bladder cancer. 展开更多
关键词 bladder neoplasm CYTOLOGY bladder tumor associated antigen nuclear matrix protein 22
下载PDF
Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens 被引量:14
2
作者 Sandra Wagner Christina S Mullins Michael Linnebacher 《World Journal of Gastroenterology》 SCIE CAS 2018年第48期5418-5432,共15页
Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hyp... Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent role of immune therapy in the clinical management of CRC. Substantial improvement in treatment outcome could be achieved by development of efficient patient-individual CRC vaccination strategies. This mini-review summarizes the current knowledge on the two general classes of targets: tumor-associated antigens(TAAs) and tumorspecific antigens. TAAs like carcinoembryonic antigen and melanoma associated antigen are present in and shared by a subgroup of patients and a variety of clinical studies examined the efficacy of different TAA-derived peptide vaccines. Combinations of several TAAs as the next step and the development of personalized TAA-based peptide vaccines are discussed. Improvements of peptidebased vaccines achievable by adjuvants and immunestimulatory chemotherapeutics are highlighted. Finally, we sum up clinical studies using tumor-specific antigens-in CRC almost exclusively neoantigens-which revealed promising results; particularly no severe adverse events were reported so far. Critical progress for clinical outcomes can be expected by individualizing neoantigen-based peptide vaccines and combining them with immunestimulatory chemotherapeutics and immune checkpoint inhibitors. In light of these data and latest developments, truly personalized neoantigen-based peptide vaccines can be expected to fulfill modern precision medicine's requirements and will manifest as treatment pillar for routine clinical management of CRC. 展开更多
关键词 Cancer vaccines COLORECTAL NEOPLASM Immunotherapy NEOPLASM antigen tumor-associated antigenS tumor-SPECIFIC antigenS Neoantigen(s)
下载PDF
Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma 被引量:12
3
作者 Yu Hong Jian Huang 《World Journal of Hepatology》 CAS 2015年第11期1581-1585,共5页
Hepatocellular carcinoma(HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early di... Hepatocellular carcinoma(HCC) is one of the most common tumors worldwide. The survival rate after the onset of symptoms is generally less than one year for the late presentation of HCC, and reliable tools for early diagnosis are lacking. Therefore, novel biomarkers for the early detection of HCC are urgently required. Recent studies show that the abnormal release of proteins by tumor cells can elicit humoral immune responses to self-antigens called tumor-associated antigens(TAAs). The corresponding autoantibodies can be detected before the clinical diagnosis of cancer. Therefore, there is growing interest in using serum autoantibodies as cancer biomarkers. In this review, we focus on the advances in research on autoantibodies against TAAs as serum biomarker for detection of HCC, the mechanism of the production of TAAs, and the association of autoantibodies with patients' clinical characteristics. 展开更多
关键词 HEPATOCELLULAR CARCINOMA Diagnosis SEROLOGICAL MARKER AUTOANTIBODY tumor associatedantigen
下载PDF
HCA520, A NOVEL TUMOR ASSOCIATED ANTIGEN, INVOLVED IN CELL PROLIFERATION AND APOPTOSIS
4
作者 杨美香 曲迅 +1 位作者 刘福利 郑广娟 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2003年第4期282-285,共4页
Objective: Tumor associated antigen encoding gene HCA520 (AF146019) was identified by screening a human hepatocellular carcinoma expressing cDNA library using SEREX technique. In this experiment we studied the effect ... Objective: Tumor associated antigen encoding gene HCA520 (AF146019) was identified by screening a human hepatocellular carcinoma expressing cDNA library using SEREX technique. In this experiment we studied the effect of HCA520 on cell proliferation and apoptosis. Methods: Gene HCA520 was gained by PCR and transfected into 293 cells. The stable expression cells were obtained by G418 selection. The cell proliferation was measured by [3H]-TdR uptake and apoptosis assay was measured by FACS. Results: Eukaryotic expression plasmid pcDNA3-HCA520 was constructed and its stable transfectants were obtained. Overexpression of HCA520 inhibited the cell proliferation and enhanced cell apoptosis after serum deprivation. Conclusion: HCA520 is a novel tumor associated antigen that can affect cell proliferation and apoptosis. 展开更多
关键词 tumor associated antigen HCA520 Sable transfected
下载PDF
Preliminary study of the diagnosis of pancreatic cancer with a serum pancreatic cancer-associated antigen
5
作者 赵晓晏 于世远 +1 位作者 郭萍 白莉 《Journal of Medical Colleges of PLA(China)》 CAS 1995年第3期162-165,共4页
The serum of 40 normal subjects, 61 cases of various malignant diseases except pancreatic cancer,53 cases of various benign diseases and 33 cases of pancreatic cancer was examined with ELISA to determine the serum lev... The serum of 40 normal subjects, 61 cases of various malignant diseases except pancreatic cancer,53 cases of various benign diseases and 33 cases of pancreatic cancer was examined with ELISA to determine the serum level of pancreatic cancer-associated ant 展开更多
关键词 PANCREATIC CANCER antigen tumor-associated CARBOHYDRATE enzyme-linked IMMUNOSORBENT assay
下载PDF
恶性肿瘤患者的抗Koc自身抗体 被引量:3
6
作者 王三英 柳珑 +3 位作者 王琳 连祺周 李祺福 彭宣宪 《中国免疫学杂志》 CAS CSCD 北大核心 2002年第1期30-32,共3页
目的:为了探讨恶性肿瘤患者的抗Koc自身抗体,研究其临床意义。方法:在优化重组Koc表达和提纯条件的基础上,以重组Koc为包被抗原,采用所建立的检测IgM、IgG、IgA类抗Koc自身抗体的ELISA技术。结果:发现抗Koc的阳性率与恶性肿瘤的类型有... 目的:为了探讨恶性肿瘤患者的抗Koc自身抗体,研究其临床意义。方法:在优化重组Koc表达和提纯条件的基础上,以重组Koc为包被抗原,采用所建立的检测IgM、IgG、IgA类抗Koc自身抗体的ELISA技术。结果:发现抗Koc的阳性率与恶性肿瘤的类型有密切关系,以肝癌、直肠癌和肺癌较高,胃癌居中,而食道癌最低,其中后者与健康对照无明显差异。以IgM、IgG、IgA中任一类Ig抗Koc对阳性为抗Koc阳性标本,肝癌、直肠癌和肺癌的阳性率均分别>50.0%,胃癌为25.5%,食道癌为15.8%,均明显较单一阳性率为高。结论:提示Ig类型抗体同步检测对于提高阳性率具有重要意义,抗Koc不失为恶性肿瘤诊断的一个良好新指标。 展开更多
关键词 恶性肿瘤 koc蛋白 肿瘤相关抗原 elisa koc自身抗体
下载PDF
抗肿瘤相关抗原P53、P62、C-myc和Koc抗体联合检测对原发性肝癌的诊断价值 被引量:4
7
作者 李志 刘卫红 +1 位作者 徐维家 张建营 《检验医学》 CAS 北大核心 2008年第3期286-289,共4页
目的对原发性肝细胞癌(HCC)患者血清中4种抗肿瘤相关抗原(TAA)抗体进行检测,探讨其对HCC的临床诊断价值。方法利用酶联免疫吸附试验(ELISA)对67例HCC患者血清和30名正常人血清中4种抗TAA(P53、P62、C-myc和Koc)抗体进行联合检测,利用电... 目的对原发性肝细胞癌(HCC)患者血清中4种抗肿瘤相关抗原(TAA)抗体进行检测,探讨其对HCC的临床诊断价值。方法利用酶联免疫吸附试验(ELISA)对67例HCC患者血清和30名正常人血清中4种抗TAA(P53、P62、C-myc和Koc)抗体进行联合检测,利用电化学发光免疫分析技术(ECLIA)对血清中甲胎蛋白(AFP)进行检测,分析其敏感性和特异性。结果每种抗TAA抗体检测结果单独判断时,敏感性都偏低,但进行不同组合后,随着种类的增多,诊断的敏感性随之增加,4种抗TAA抗体联合检测的敏感性达到了82.1%,明显高于AFP的敏感性(68.7%),特异性达到了86.7%,阳性预测值93.2%,阴性预测值68.4%。结论利用4种抗TAA抗体联合检测能够提高HCC的诊断质量,降低漏诊率,为HCC患者临床早期诊断和高危人群筛查,以及AFP阴性的HCC患者补充测定提供了一种新方法。 展开更多
关键词 肝细胞癌 诊断 肿瘤相关抗原 抗体 免疫测定
下载PDF
ELISA检测肿瘤相关抗原CA19-9的方法学评价
8
作者 董振南 丁慧 +2 位作者 贾兴旺 金剑 田亚平 《标记免疫分析与临床》 CAS 2009年第5期294-295,共2页
对肿瘤相关抗原CA19-9酶联免疫法(ELISA法)进行方法学评价。选取各类标本204份,将本方法的灵敏度、特异性、阳性预测值、阴性预测值与电化学发光免疫分析(ECLIA)的进行比较并综合分析。本方法检测的灵敏度为52.5%,特异性为82.9%,阳性预... 对肿瘤相关抗原CA19-9酶联免疫法(ELISA法)进行方法学评价。选取各类标本204份,将本方法的灵敏度、特异性、阳性预测值、阴性预测值与电化学发光免疫分析(ECLIA)的进行比较并综合分析。本方法检测的灵敏度为52.5%,特异性为82.9%,阳性预测值为82.1%,阴性预测值为54.0%。以ECLIA为相对标准,相对灵敏度为100%,相对特异性为100%,相对符合率为100%,与ECLIA相关性显著,r2=0.9749。相关分析结果表明,ELISA与ECLIA相关性好。本方法试剂稳定,结果准确、可靠,有很高的特异性。 展开更多
关键词 肿瘤相关抗原 CA19-9 酶联免疫法 电化学发光免疫法 消化道肿瘤
下载PDF
Chimeric antigen receptor-engineered T-cell therapy for liver cancer 被引量:20
9
作者 Yang Chen Chang-Yong E +4 位作者 Zhi-Wen Gong Shui Liu Zhen-Xiao Wang Yong-Sheng Yang Xue-Wen Zhang 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2018年第4期301-309,共9页
Background: Chimeric antigen receptor-engineered T-cell(CAR-T) therapy is a newly developed immunotherapy used in the treatment of cancers. Because CAR-T therapy has shown great success in treating CD19-positive hemat... Background: Chimeric antigen receptor-engineered T-cell(CAR-T) therapy is a newly developed immunotherapy used in the treatment of cancers. Because CAR-T therapy has shown great success in treating CD19-positive hematological malignancies, its application has been explored in the treatment of solid tumors, such as liver cancer. In this review, we discuss the immune characteristics of liver cancer, the obstacles encountered during the application of CAR-T therapy, and preclinical and clinical progress in the use of CAR-T therapy in patients with liver cancer.Data sources: The data on CAR-T therapy related to liver cancers were collected by searching Pub Med and the Web of Science databases prior to December 2017 with the keywords "chimeric antigen receptor","CAR-T", "liver cancer", "hepatocellular carcinoma", and "solid tumor". Additional articles were identified by manual search of references found in the primary articles. The data for clinical trials were collected by searching Clinical Trials.gov.Results: The liver has a tolerogenic nature in the intrahepatic milieu and its tumor microenvironment significantly affects tumor progression. The obstacles that reduce the efficacy of CAR-T therapy in solid tumors include a lack of specific tumor antigens, limited trafficking and penetration of CAR-T cells to tumor sites, and an immunosuppressive tumor microenvironment. To overcome these obstacles, several strategies have emerged. In addition, several strategies have been developed to manage the side effects of CAR-T, including enhancing the selectivity of CARs and controlling CAR-T activity. To date, no clinical trials of CAR-T therapy against HCC have been completed. However, preclinical studies in vitro and in vivo have shown potent antitumor efficacy. Glypican-3, mucin-1, epithelial cell adhesion molecule, carcinoembryonic antigen, and other targets are currently being studied.Conclusions: The application of CAR-T therapy for liver cancer is just beginning to be explored and more research is needed. However, we are optimistic that CAR-T therapy will offer a new approach for the treatment of liver cancers in the future. 展开更多
关键词 Liver cancer Chimeric antigen receptor-engineered T-cell THERAPY IMMUNOTHERAPY tumor-associated antigen
下载PDF
Identification of novel HLA-A 0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer 被引量:1
10
作者 Hyun Ju Lee Cheol Yi Hong +8 位作者 Chun-Ji Jin Mi-Hyun Kim Youn-Kyung Lee Thanh-Nhan Nguyen-Pham Hyunah Lee Byoung Chul Park Ik-Joo Chung Hyeoung-Joon Kim Je-Jung Lee 《Cellular & Molecular Immunology》 SCIE CAS CSCD 2012年第2期175-183,共9页
Anterior gradient-2 (AGR2) promotes tumor growth, cell migration and cellular transformation and its enhanced expression is almost completely restricted to malignant tissues, thus making AGR2 an interesting target f... Anterior gradient-2 (AGR2) promotes tumor growth, cell migration and cellular transformation and its enhanced expression is almost completely restricted to malignant tissues, thus making AGR2 an interesting target for the development of immunotherapeutic strategies. We investigated whether the AGR2 molecule comprises human leukocyte antigen (HLA)-A 0201-binding epitopes recognized by human cytotoxic T lymphocytes (CTLs), which could be targeted in dendritic cell (DC)-based cancer immunotherapy against colorectal cancer (CRC). We reviewed the sequence of AGR2 for peptides that could potentially bind to HLA-A 0201 with the aid of a computer-based program. Five candidate peptides with different binding scores were synthesized and tested. These peptides were then assessed for their immunogenicity to elicit specific immune responses mediated by CTLs in vitro by means of enzyme-linked immunospot assays and CTL assays. AGR2 was highly expressed in several CRC cell lines, including DK01, DLD1, KM 12C, HCT-8 and HT-29. DCs pulsed with AGR2-P2 (aa 11-19; LLVALSYTL) or AGR2-P4 (aa 127-135; RIMFVDPSL) generated potent CTLs that could lyse T2 cells pulsed with AGR2-P2 or AGR2-P4 and HLA-A0201+ AGR2-positive CRC cell lines in a strong dose-dependent and HLA-A 0201-restricted manner. In conclusion, these novel epitopes derived from AGR2 protein may be attractive candidates for DC-based immunotherapy for CRC. 展开更多
关键词 AGR2 colorectal cancer dendritic cell tumor-associated antigen
原文传递
A Novel Putative Tumor Associated Antigen
11
作者 白芸 于天维 +3 位作者 赵颖旭 肖翌 杨宇丰 陈应华 《Tsinghua Science and Technology》 SCIE EI CAS 1999年第3期1568-1569,共2页
A is a tumor associated antigen. Monoclonal antibody (mAb) against 17 1A has been used in adjuvant therapy of colorectal carcinoma. Using mAb against 17 1A antigen on affinity chromatography, a novel putative tumor ... A is a tumor associated antigen. Monoclonal antibody (mAb) against 17 1A has been used in adjuvant therapy of colorectal carcinoma. Using mAb against 17 1A antigen on affinity chromatography, a novel putative tumor associated antigen (P50) whose relative molecular mass is 5 0×10 4 has been isolated from human colorectal tumor tissues which are recognized by mAbs 17 1A and M79, while the relative molecular mass of 17\|1A antigen isolated from several colorectal tumor cell lines is 3 3×10 4. P50 was recognized by mAbs 17 1A and M79 which are specific mAbs against 17 1A antigen. 展开更多
关键词 A antigen colorectal tumor tissue tumor associated antigen
原文传递
Improved detection Of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay
12
作者 Sinang Chourb Brian Christopher Mackness +1 位作者 Leslie Ruth Farris Melisenda Jean McDonald 《Health》 2011年第8期524-528,共5页
Breast cancer is the second leading cause of cancerrelated deaths in women worldwide;a prime cancer biomarker to aid in the diagnosis, directed treatment, clinical management, and reoccurrence of this cancer is a MUC1... Breast cancer is the second leading cause of cancerrelated deaths in women worldwide;a prime cancer biomarker to aid in the diagnosis, directed treatment, clinical management, and reoccurrence of this cancer is a MUC1 peptide fragment: cancer antigen 15-3 (CA 15-3). Herein, an immuno-fluorescence assay for CA 15-3 was developed;this ALYGNSA system consists of a protein biolinker (Protein G’) adsorbed onto Poly (methyl methacrylate) (PMMA). The unique interaction of Protein G’ with PMMA, a thermo-plastic polymer has been demonstrated to improve human IgG capture antibody alignment/ orientation and result in greater assay sensitivity. Indeed a previous report (HEALTH 1 325 - 329, 2009) on the shed extracellular domain of HER-2/neu revealed a 10-fold increase in sensitivity of the ALYGSNA assay over a control ELISA assay. Results from this ALYGNSA assay study revealed that a 16-fold increase in detection (≤0.94 U/mL) of CA 15-3 was found in comparison to a commercial control ELISA kit (≤15 U/mL). In conclusion, this enhanced sensitivity of the ALYGNSA assay for CA 15-3, may provide insights into the role/function of this biomarker in normal, as well as, breast cancer and other epithelial cancers. 展开更多
关键词 CA 15-3 CANCER antigen 15-3 EPITHELIAL tumor antigen MUC1 Breast CANCER Marker elisa Fluorescent IMMUNOASSAY ALYGNSA
下载PDF
57例妇女血清宫颈癌抗原ELISA检测
13
作者 邬珊 王佑华 《九江医学》 1994年第3期150-151,共2页
用小鼠宫颈癌单抗(AU_(14-1))对57例妇女血清作ELISA分析,以检测宫颈癌抗原。其中宫颈癌患者10例,宫颈炎37例,子宫内膜场2例,宫颈正常8例。结果:ELISA阳性率,宫颈癌者为100%,宫颈炎为8.1%... 用小鼠宫颈癌单抗(AU_(14-1))对57例妇女血清作ELISA分析,以检测宫颈癌抗原。其中宫颈癌患者10例,宫颈炎37例,子宫内膜场2例,宫颈正常8例。结果:ELISA阳性率,宫颈癌者为100%,宫颈炎为8.1%,子宫内膜癌为0,宜颈正常者为12.5%。表明该法对宫颈癌的检测具有重要价值,且简单方便,经济省时,有可能成为宫颈癌的大面积普查、筛选的一新手段。 展开更多
关键词 宫颈癌 抗原 抗体 单克隆抗体 elisa 免疫诊断
下载PDF
MAGEA12在胃肠道间质瘤中的表达及其与危险度分级的关系
14
作者 仲铭洋 于卓群 +3 位作者 兰东旭 程周扬 吴寒 支小飞 《南通大学学报(医学版)》 2024年第2期107-111,共5页
目的:探讨胃肠道间质瘤(gastrointestinal stromal tumors,GIST)中黑色素瘤相关抗原基因A12(melanomaassociated antigen gene A12,MAGEA12)的表达水平及其与GIST危险度分级的关系。方法:收集5例GIST患者的肿瘤组织及癌旁组织,采用转录... 目的:探讨胃肠道间质瘤(gastrointestinal stromal tumors,GIST)中黑色素瘤相关抗原基因A12(melanomaassociated antigen gene A12,MAGEA12)的表达水平及其与GIST危险度分级的关系。方法:收集5例GIST患者的肿瘤组织及癌旁组织,采用转录组测序的方法,通过主成分分析(principal components analysis,PCA)、基因集富集分析(gene set enrichment analysis,GSEA)及差异表达基因分析法,明确GIST组织异常信号通路及异常表达基因;采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)法验证90对GIST组织中异常表达基因MAGEA12的表达水平,并通过χ2检验分析MAGEA12的表达水平与GIST患者临床病理特征的相关性。结果:PCA显示GIST组织基因表达谱与癌旁组织比较差异有统计学意义;GSEA发现,GIST组织中多种肿瘤相关信号通路异常高表达;差异表达基因分析发现,MAGEA12是GIST组织中表达上调最高的基因(表达升高25倍);qRT-PCR验证了MAGEA12在GIST样本中显著高表达,且与GIST危险度分级呈正相关。结论:MAGEA12在GIST中高表达,其表达水平与GIST危险度相关,可能成为治疗的新靶点。 展开更多
关键词 胃肠道间质瘤 黑色素瘤相关抗原基因A12 危险度分级
下载PDF
胃腺癌中抗原处理相关转运蛋白1的表达和临床意义
15
作者 陈兰丝 李嘉豪 +3 位作者 杨春秀 谢吻 肖书渊 熊斌 《实用肿瘤杂志》 CAS 2024年第5期456-462,共7页
目的探讨胃腺癌(stomach adenocarcinoma,STAD)中抗原处理相关转运蛋白1(transporter associated with antigen processing 1,TAP1)表达与临床病理特征的关系及其预后意义。方法通过癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据... 目的探讨胃腺癌(stomach adenocarcinoma,STAD)中抗原处理相关转运蛋白1(transporter associated with antigen processing 1,TAP1)表达与临床病理特征的关系及其预后意义。方法通过癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库收集TAP1在STAD组织中的mRNA表达水平和患者临床资料。采用GraphPad Prism软件分析TAP1表达与临床病理特征的关系,采用Kaplan-Meier曲线分析其与患者总生存期的关系。采用蛋白质印迹法检测STAD细胞株MKN45和AGS以及人正常胃黏膜上皮细胞株GES-1中TAP1的蛋白表达。收集2020年1月1日至12月31日武汉大学中南医院病理科的STAD组织标本122例和2020年10月1日至12月31日武汉大学中南医院病理科的正常胃切除标本24例,采用免疫组织化学法检测组织中的TAP1表达,分析其与患者临床病理特征的关系。结果TCGA数据库分析和组织标本的免疫组织化学分析均显示,TAP1在STAD组织中较正常胃组织高表达(均P<0.05)。TAP1在STAD细胞株MKN45中的表达较正常胃黏膜上皮细胞株GES-1高(P<0.01),而人STAD细胞株AGS与GES-1中TAP1水平比较,差异无统计学意义(P>0.05)。在STAD组织中,TAP1蛋白表达水平在STAD的Laurén分型方面比较,差异具有统计学意义(P<0.05)。TCGA数据库分析发现,TAP1表达水平随肿瘤组织分级的增加而升高(P<0.05)。TCGA数据库中STAD患者按TAP1表达中位数6.82分为TAP1高表达组和低表达组。TAP1高表达组中位总生存期更长(57.1个月vs 25.1个月,P<0.05)。结论TAP1在STAD组织中高表达,且与Laurén分型和组织分级相关,为预后保护因素,可作为STAD预后的潜在标志物。 展开更多
关键词 胃腺癌 抗原处理相关转运蛋白1 肿瘤免疫 抗原呈递
下载PDF
恶性肿瘤中免疫检查点抑制剂与甲状腺功能异常风险的Meta分析
16
作者 明慧 余辉 +1 位作者 陈启超 陈援浩 《肿瘤综合治疗电子杂志》 2024年第1期111-121,共11页
目的 Meta分析免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗引起恶性肿瘤患者发生甲状腺功能异常的风险。方法 检索从建库至2022年10月15日Pub Med、Embase、Cochrane Library、中国知网及万方医学网中关于恶性肿瘤ICIs治... 目的 Meta分析免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)治疗引起恶性肿瘤患者发生甲状腺功能异常的风险。方法 检索从建库至2022年10月15日Pub Med、Embase、Cochrane Library、中国知网及万方医学网中关于恶性肿瘤ICIs治疗的相关不良反应研究。根据纳入与排除标准筛选文献,提取研究数据,采用Stata 12.0软件进行Meta分析。结果 共纳入32项随机对照试验,其中使用程序性细胞死亡蛋白1(programmed cell death protein-1,PD-1)、程序性细胞死亡配体1(programmed cell death ligand-1,PD-L1)、细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte-associated antigen-4,CTLA-4)抑制剂单药治疗分别为17篇、6篇、3篇,两种ICIs联合使用为8篇。Meta分析显示,ICIs单药治疗引起恶性肿瘤患者发生甲状腺功能减退(RR=9.04,95%CI为7.21~11.33)、甲状腺功能亢进(RR=10.83,95%CI为6.96~16.90)、甲状腺炎(RR=7.61,95%CI为2.99~19.37)的风险明显高于对照组。PD-1(RR=8.61,95%CI为6.47~11.46)、PD-L1(RR=6.75,95%CI为4.33~10.52)、CTLA-4(RR=7.12,95%CI为3.16~16.08)和联合应用(RR=52.56,95%CI为13.15~210.12)引起的甲状腺功能减退的风险比对照组均升高。与单一ICIs比较,ICIs联合使用引起甲状腺功能减退(RR=1.77,95%CI为1.41~2.22)及甲状腺功能亢进(RR=3.79,95%CI为2.42~5.96)的风险进一步升高。结论 ICIs治疗引起恶性肿瘤患者甲状腺功能异常的风险明显升高,以发生甲状腺功能减退的风险最高,其次是甲状腺功能亢进和甲状腺炎。与ICIs单药比较,ICIs联合使用可进一步升高风险。 展开更多
关键词 免疫检查点抑制剂 程序性细胞死亡蛋白1 程序性细胞死亡配体1 细胞毒性T淋巴细胞相关蛋白4 甲状腺功能异常 恶性肿瘤
下载PDF
miR-487a通过靶向调控TIA1对胃癌肿瘤相关巨噬细胞M2型极化的抑制作用
17
作者 曲颜 戴霖 +3 位作者 王彪 阮笃激 钟裕昌 杨雪峰 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2024年第3期728-738,共11页
目的:探讨微小RNA(miR)-487a对胃癌肿瘤相关巨噬细胞(TAMs) M2型极化的抑制作用,并阐明其对胃癌AGS细胞增殖、侵袭和迁移的影响。方法:分离和培养原发性胃癌患者胃癌组织TAMs及癌旁组织来源的正常巨噬细胞(NTMs),体外诱导人单核细胞THP-... 目的:探讨微小RNA(miR)-487a对胃癌肿瘤相关巨噬细胞(TAMs) M2型极化的抑制作用,并阐明其对胃癌AGS细胞增殖、侵袭和迁移的影响。方法:分离和培养原发性胃癌患者胃癌组织TAMs及癌旁组织来源的正常巨噬细胞(NTMs),体外诱导人单核细胞THP-1分化为TAMs,将分化得到的M0、M1和M2型巨噬细胞经条件培养基(CM)刺激培养24 h,分别获取TAMs、M1-TAMs和M2-TAMs。转染TAMs,分为空白组、 inhibitor-NC组、 miR-487a inhibitor组、 miR-487a inhibitor+si-NC组和miR-487ainhibitor+si-TIA1组,采用实时荧光定量PCR(RT-qPCR)法和Western blotting法验证转染效率。将M2-TAMs与AGS细胞共培养,分为AGS组、AGS+inhibitor-NC组、AGS+miR-487ainhibitor组、AGS+miR-487ainhibitor+si-NC组和AGS+miR-487ainhibitor+si-TIA1组,RT-qPCR法检测胃癌组织TAMs和癌旁组织NTMs及各组TAMs中miR-487a和T淋巴细胞胞浆内抗原-1(TIA1) mRNA表达水平,Western blotting法检测胃癌组织TAMs和癌旁组织NTMs及各组TAMs中TIA1蛋白表达水平,流式细胞术检测各组TAMs中CD206和CD163水平,酶联免疫吸附试验(ELISA)法检测各组TAMs培养上清中白细胞介素10(IL-10)、转化生长因子β(TGF-β)、血管内皮生长因子A(VEGF-A)和精氨酸酶1(Arg-1)水平,CCK-8法检测各组AGS细胞增殖活性,细胞划痕实验检测各组AGS细胞迁移率,Transwell实验检测各组AGS细胞侵袭细胞数。结果:RT-qPCR法,与癌旁组织NTMs比较,胃癌组织TAMs中miR-487a表达水平明显升高(P<0.01),TIA1 mRNA表达水平明显降低(P<0.01);与TAMs比较,M1-TAMs中miR-487a表达水平明显降低(P<0.01),TIA1 mRNA表达水平明显升高(P<0.01);M2-TAMs中miR-487a表达水平明显升高(P<0.01),TIA1 mRNA表达水平明显降低(P<0.01);转染后,与空白组和inhibitor-NC组比较,miR-487a inhibitor组细胞中miR-487a表达水平明显降低(P<0.01),提示细胞转染成功。Western blotting法,与癌旁组织NTMs比较,胃癌组织TAMs中TIA1蛋白表达水平明显降低(P<0.01);与TAMs比较,M1-TAMs中TIA1蛋白表达水平明显升高(P<0.01),M2-TAMs中TIA1蛋白表达水平明显降低(P<0.01);共转染后,与inhibitor-NC组比较,miR-487a inhibitor组细胞中TIA1蛋白表达水平明显升高(P<0.01);与miR-487a inhibitor+si-NC组比较,miR-487a inhibitor+si-TIA1组细胞中TIA1蛋白表达水平明显降低(P<0.01)。流式细胞术,与空白组和inhibitor-NC组比较,miR-487a inhibitor组细胞中CD206和CD163水平明显降低(P<0.01);共转染后,与inhibitor-NC组比较,miR-487a inhibitor组细胞中CD206和CD163水平均明显降低(P<0.01);与miR-487a inhibitor+si-NC组比较,miR-487a inhibitor+si-TIA1组细胞中CD206和CD163水平均明显升高(P<0.01)。ELISA法,与空白组和inhibitor-NC组比较,miR-487a inhibitor组TAMs细胞培养上清中IL-10、TGF-β、VEGF-A和Arg-1水平均明显降低(P<0.01);共转染后,与inhibitor-NC组比较,miR-487a inhibitor组TAMs细胞培养上清中IL-10、TGF-β、VEGF-A和Arg-1水平均明显降低(P<0.01);与miR-487a inhibitor+si-NC组比较,miR-487a inhibitor+si-TIA1组TAMs细胞培养上清中IL-10、TGF-β、VEGF-A和Arg-1水平均明显升高(P<0.01)。CCK-8法,与AGS组比较,AGS+inhibitor-NC组细胞增殖活性明显升高(P<0.01);与AGS+inhibitor-NC组比较,AGS+miR-487a inhibitor组细胞增殖活性明显降低(P<0.01);与AGS+miR-487a inhibitor+si-NC组比较,AGS+miR-487a inhibitor+si-TIA1组细胞增殖活性明显升高(P<0.01)。细胞划痕实验,与AGS组比较,AGS+inhibitor-NC组AGS细胞迁移率明显升高(P<0.05);与AGS+inhibitor-NC组比较,AGS+miR-487a inhibitor组AGS细胞迁移率明显降低(P<0.01);与AGS+miR-487a inhibitor+si-NC组比较,AGS+miR-487a inhibitor+si-TIA1组AGS细胞迁移率明显升高(P<0.05)。Transwell实验,与AGS组比较,AGS+inhibitorNC组AGS细胞侵袭细胞数明显升高(P<0.01);与AGS+inhibitor-NC组比较,AGS+miR-487a inhibitor组AGS细胞侵袭细胞数明显降低(P<0.01);与AGS+miR-487a inhibitor+si-NC组比较,AGS+miR-487a inhibitor+si-TIA1组AGS细胞侵袭细胞数明显升高(P<0.01)。结论:沉默miR-487a表达可通过靶向上调TIA1抑制胃癌肿瘤相关巨噬细胞M2型极化,并抑制胃癌细胞增殖、迁移和侵袭。 展开更多
关键词 胃肿瘤 微小RNA-487a T淋巴细胞内抗原1 肿瘤相关巨噬细胞 M2型极化
下载PDF
过表达M2型肿瘤相关巨噬细胞TIA1基因通过调控PI3K/AKT信号通路抑制胃癌细胞侵袭和迁移
18
作者 钟裕昌 阮笃激 +3 位作者 戴霖 王彪 曲颜 杨雪峰 《中国免疫学杂志》 CAS CSCD 北大核心 2024年第8期1658-1664,共7页
目的:探讨过表达M2型肿瘤相关巨噬细胞(M2-TAMs)T淋巴细胞内抗原1(TIA1)基因对胃癌BGC-823细胞侵袭和迁移的影响及其机制。方法:从胃癌组织中提取原代TAMs,采用IL-4和IL-13刺激TAMs诱导分化成M2-TAMs,再将TIA1基因过表达质粒(oe-TIA1)... 目的:探讨过表达M2型肿瘤相关巨噬细胞(M2-TAMs)T淋巴细胞内抗原1(TIA1)基因对胃癌BGC-823细胞侵袭和迁移的影响及其机制。方法:从胃癌组织中提取原代TAMs,采用IL-4和IL-13刺激TAMs诱导分化成M2-TAMs,再将TIA1基因过表达质粒(oe-TIA1)及其空载质粒(Vector)转染至M2-TAMs中,采用qRT-PCR和Western blot检测细胞中TIA1 mRNA和蛋白表达水平;流式细胞术检测细胞中CD206和CD163表达水平;ELISA检测细胞培养上清液中IL-10、TGF-β、VEGF-A和Arg-1水平。通过Transwell共培养体系将转染后的M2-TAMs与胃癌BGC-823细胞共培养,并联用PI3K激动剂740Y-P进行干预,采用划痕实验检测细胞迁移能力;Transwell实验检测细胞侵袭能力;Western blot检测细胞中PI3K、p-PI3K、AKT、p-AKT、MMP-2和MMP-9等蛋白表达水平。结果:①与原代TAMs比较,M2-TAMs中CD206和CD163表达水平及细胞培养上清液中IL-10、TGF-β、VEGF-A和Arg-1水平均显著升高(P<0.05),而TIA1 mRNA和蛋白表达水平显著降低(P<0.05)。TIA1基因过表达可显著降低M2-TAMs中CD206和CD163表达水平及细胞培养上清液中IL-10、TGF-β、VEGF-A和Arg-1水平(P<0.05)。②M2-TAMs中过表达TIA1基因可显著降低BGC-823细胞迁移和侵袭能力及p-PI3K/PI3K、p-AKT/AKT、MMP-2和MMP-9等蛋白表达水平(P<0.05)。③740Y-P可显著逆转M2-TAMs中过表达TIA1基因对BGC-823细胞迁移、侵袭及PI3K/AKT信号通路的抑制作用。结论:过表达M2-TAMs中TIA1基因表达可通过阻断PI3K/AKT信号通路影响胃癌细胞侵袭和迁移。 展开更多
关键词 M2型肿瘤相关巨噬细胞 T淋巴细胞内抗原1 胃癌细胞 PI3K/AKT信号通路
下载PDF
P16、Ki67在宫颈癌组织中表达水平及其与临床特征、预后的关系
19
作者 杨柳荫 靳小飞 高云燕 《航空航天医学杂志》 2024年第10期1157-1159,共3页
目的探讨抑癌基因P16(P16)、增殖细胞相关抗原(Ki67)在宫颈癌组织中表达水平及其与临床特征、预后的关系。方法选取我院收治的宫颈癌患者82例,用免疫组织化学法检测癌组织及癌旁正常组织中的P16、Ki67的表达。分析P16、Ki67在宫颈癌组... 目的探讨抑癌基因P16(P16)、增殖细胞相关抗原(Ki67)在宫颈癌组织中表达水平及其与临床特征、预后的关系。方法选取我院收治的宫颈癌患者82例,用免疫组织化学法检测癌组织及癌旁正常组织中的P16、Ki67的表达。分析P16、Ki67在宫颈癌组织中表达水平及其与临床特征、预后的关系。结果癌组织P16、Ki67的阳性表达率分别为74.39%、70.73%,高于癌旁组织的18.29%、20.73%(P<0.05)。肿瘤大小>4 cm、TNM分期T3期、浸润深度>1/3肌层癌组织P16、Ki67阳性表达率分别为90.91%、87.88%,92.11%、94.74%,90.91%、90.91%,高于肿瘤大小≤4 cm、TNM分期T1~T2期、浸润深度≤1/3肌层癌组织的63.27%、59.18%,59.09%、50.00%,68.33%、63.33%(P<0.05)。非术后1年无进展生存宫颈癌患者宫颈癌组织P16、Ki67表达阳性率95.24%、90.48%,高于术后1年无进展生存宫颈癌患者的67.21%、63.93%(P<0.05)。结论P16、Ki67在宫颈癌组织中表达增加,且与临床特征、预后密切相关。 展开更多
关键词 宫颈癌 抑癌基因P16 增殖细胞相关抗原 临床特征 预后
下载PDF
血清癌胚抗原相关细胞黏附分子1 脂质运载蛋白-2 恶性肿瘤特异生长因子联合检测鉴别诊断乳腺癌的价值
20
作者 徐梦霜 曾强 《实用医技杂志》 2024年第3期195-197,共3页
目的 探讨血清癌胚抗原相关细胞黏附分子1(CEACAM1)、脂质运载蛋白2(LCN-2)、恶性肿瘤特异生长因子(TSGF)联合检测鉴别诊断乳腺癌的价值。方法 本研究为回顾性分析,对我院2021年1月至2023年1月收治的40例良性乳腺肿瘤患者临床资料进行收... 目的 探讨血清癌胚抗原相关细胞黏附分子1(CEACAM1)、脂质运载蛋白2(LCN-2)、恶性肿瘤特异生长因子(TSGF)联合检测鉴别诊断乳腺癌的价值。方法 本研究为回顾性分析,对我院2021年1月至2023年1月收治的40例良性乳腺肿瘤患者临床资料进行收集,作为对照组;并对同期医院收治的40例乳腺癌患者临床资料进行收集,作为观察组。设计基线资料填写表,详细对2组基线资料、血清检查指标进行填写、比较,重点分析血清CEACAM1、LCN-2、TSGF联合检测鉴别诊断乳腺癌的价值。结果 观察组血清CEACAM1、LCN-2、TSGF水平比对照组高,差异有统计学意义(P<0.05),组间年龄、体质指数(BMI)、肿瘤直径、绝经及患侧比较,差异无统计学意义(P>0.05);绘制受试者工作曲线(ROC)结果显示,血清CEACAM1、LCN-2、TSGF检测鉴别诊断乳腺癌的曲线下面积(AUC)均>0.70,且以联合检测(并联)价值最佳。结论 血清CEACAM1、LCN-2、TSGF联合检测鉴别诊断乳腺癌有较高的灵敏度、特异度,鉴别诊断价值满意。 展开更多
关键词 乳腺肿瘤 癌胚抗原相关细胞黏附分子1 脂质运载蛋白2 恶性肿瘤特异生长因子 鉴别诊断
下载PDF
上一页 1 2 24 下一页 到第
使用帮助 返回顶部